COVID-19 Death and BCG Vaccination Programs Worldwide
| Autor: | Feras J. Jirjees, Yahya H. Dallal Bashi, Hala J. Al-Obaidi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Tuberculosis and Respiratory Diseases, Vol 84, Iss 1, Pp 13-21 (2021) |
| Druh dokumentu: | article |
| ISSN: | 1738-3536 2005-6184 |
| DOI: | 10.4046/trd.2020.0063 |
| Popis: | Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|